Cosentyx Drug Market Report 2026

Cosentyx Drug Market Overview

• The Cosentyx Drug market growth in the historic period has been driven by approval of il 17 inhibitors, high prevalence of psoriasis and arthritis • Market expansion is supported by growth in autoimmune disease diagnosis, expansion of treatment indications • Growth Driver: Impact Of Rising Autoimmune Disease Prevalence On The Growth Of The Cosentyx Market • Market Trend: Advancing Treatment Paradigms With Biologic Innovations And Market Strategies In The Cosentyx Drug Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Cosentyx Drug Market?

Cosentyx (secukinumab) is a prescription biologic medication developed by Novartis. It is a monoclonal antibody that inhibits interleukin-17A (IL-17A), a protein involved in inflammation. Cosentyx is primarily used to treat autoimmune conditions such as plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. It is administered via subcutaneous injection and helps reduce inflammation, skin symptoms, and joint damage. The drug has shown efficacy in improving the quality of life for patients with these chronic conditions. The main indication types of cosentyx drugs are hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis. Hidradenitis suppurativa is a chronic skin condition causing painful lumps, abscesses, and scarring, typically in areas with sweat glands such as underarms and groin. The routes of administration are subcutaneous injection and intravenous infusion and distribution channels are hospital pharmacies, online pharmacies, and retail pharmacies.

What Is The Cosentyx Drug Market Growth Forecast?

The cosentyx drug market size is expected to see strong growth in the next few years. It will grow to $8.74 million in 2030 at a compound annual growth rate (CAGR) of 8.9%. The growth in the forecast period can be attributed to growth in autoimmune disease diagnosis, expansion of treatment indications, increasing patient awareness, improved biologic accessibility, long term efficacy data support. Major trends in the forecast period include growing adoption of il 17 inhibitor therapies, expansion of use across autoimmune indications, shift toward targeted biologic treatments, increased use of long term maintenance therapy, rising demand for self injectable biologics.

Global Cosentyx Drug Market Segmentation

1) By Indication: Hidradenitis suppurativa, Psoriatic arthritis, Ankylosing spondylitis, Plaque Psoriasis 2) By Route Of Administration: Subcutaneous injection, Intravenous infusion 3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies

What Are The Drivers Of The Cosentyx Drug Market?

The rising prevalence of autoimmune diseases is expected to propel the growth of cosentyx market going forward. Autoimmune diseases refer to disorders characterized by the immune system mistakenly attacking the body's healthy cells and tissues. The rising prevalence of autoimmune diseases is attributed to genetic predisposition, environmental factors (such as infections and pollutants), and lifestyle changes, including increased stress and dietary shifts. Cosentyx (secukinumab) helps autoimmune disease patients by targeting and inhibiting interleukin-17A, a key cytokine involved in the inflammatory process, thereby reducing symptoms, improving quality of life, and managing conditions such as psoriasis, psoriatic arthritis, and ankylosing spondylitis effectively. For instance, in August 2024, according to the data from Public Health Scotland, a Scotland-based national organization, reported that in 2023, the Scottish Multiple Sclerosis Register (SMSR) recorded 455 newly diagnosed MS patients. Therefore, the rising prevalence of autoimune diseases drives the cosentyx market. Rising healthcare expenditure is expected to propel the growth of the cosentyx market going forward. Healthcare expenditure refers to the total amount spent on healthcare goods and services, including personal health care, preventive services, and public health activities, aimed at improving health outcomes within a specific period. The rising healthcare expenditure is due to an aging population, chronic diseases, advanced medical technology, high drug prices, inefficient payment models, and increased demand for services. Healthcare expenditure for Cosentyx is primarily directed toward managing moderate to severe psoriasis, psoriatic arthritis, and ankylosing spondylitis, improving patient outcomes through targeted biologic therapy. For instance, in May 2024, according to a report published by Office for National Statistics, a UK-based government agency, total healthcare expenditure rose by 5.6% in nominal terms from 2022 to 2023, compared to a growth rate of 0.9% in 2022. Therefore, the rising healthcare expenditure is driving the cosentyx market.

Key Players In The Global Cosentyx Drug Market

Major companies operating in the cosentyx drug market are Novartis AG

Global Cosentyx Drug Market Trends and Insights

Major companies operating in the cosentyx drug market are focusing on developing advanced therapies such as biological treatment options to address unmet medical needs, enhance treatment efficacy, and provide targeted therapies for managing chronic autoimmune conditions, thereby strengthening their market position and catering to a growing patient population. Biologic treatments are advanced therapies derived from living organisms or their cells that specifically target components of the immune system, such as interleukin-17A, to modulate inflammatory responses and effectively treat autoimmune conditions such as psoriasis, psoriatic arthritis, and ankylosing spondylitis. For instance, in October 2023, Novartis AG, a Switzerland-based pharmaceutical company, received FDA approval for Cosentyx (secukinumab) as the first new biologic treatment option for moderate to severe hidradenitis suppurativa (HS) in nearly a decade. This approval marks a significant advancement in the treatment landscape for HS, a chronic and often debilitating skin condition characterized by painful lumps that can lead to scarring and psychological distress.

Regional Insights

North America was the largest region in the cosentyx drug market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Cosentyx Drug Market?

The cosentyx drug market consists of sales oflyophilized powder, and self-administered autoinjector. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Cosentyx Drug Market Report 2026?

The cosentyx drug market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the cosentyx drug industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.